- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears AI-Enabled Denoising Feature for DWI Sequences on Portable Brain MRI System
In reportedly the eighth FDA 510(k) clearance for Hyperfine’s Swoop portable brain MRI device, clinicians will now have access to enhanced denoising capabilities with diffusion-weighted imaging (DWI) sequences.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the addition of artificial intelligence (AI)-powered denoising to diffusion-weighted imaging (DWI) sequences with the portable brain MRI system Swoop (Hyperfine).
Hyperfine said the expanded denoising capability, previously added with the device’s T1, T2 and FLAIR MRI sequences, will provide crisper imaging and improved diagnostic accuracy with DWI sequences.
“We believe in making brain imaging more accessible, clinically relevant, and actionable. We continue to make meaningful progress across all sequences. With this significant and most recent update, we now incorporate deep learning into our DWI sequence,” said Tom Teisseyre, the chief operating officer of Hyperfine. “These imaging improvements will serve a critical role in enhancing image quality for healthcare professionals in time-sensitive environments.”
The company added the FDA nod is the eighth 510(k) clearance for the Swoop device and plans to add the DWI software update in the coming months.
Seven Takeaways from New CT and MRI Guidelines for Ovarian Cancer Staging
January 20th 2025In an update of previous guidelines from the European Society of Urogenital Radiology published in 2010, a 21-expert panel offered consensus recommendations on the utility of CT, MRI and PET-CT in the staging and follow-up imaging for patients with ovarian cancer.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
